CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$57.92 USD
+0.35 (0.61%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $58.50 +0.58 (1.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.92 USD
+0.35 (0.61%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $58.50 +0.58 (1.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Zacks News
Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates
by Zacks Equity Research
The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.
Why You Should Invest in Genomics ETFs
by Neena Mishra
Genomics ETFs have surged of late; here's why
Vertex to End Phase II Study on AAT Deficiency Candidate
by Zacks Equity Research
Vertex (VRTX) to discontinue phase II study on VX-814 based on the liver enzyme elevations observed and the determination that it would be difficult to safely achieve targeted exposure levels.
Booming Gene Editing Market to Pep Up These 5 Biotech Stocks
by Zacks Equity Research
Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.
The Innovative Future Of ETFs
by Daniel Laboe
Ark Invest is driving a new generation of actively managed ETFs
Big October Winners: CRISPR, Alteryx, NVIDIA, Quidel
by Kevin Cook
Two women will share the Nobel prize for a gene editing technology that will change the world.
CRISPR Therapeutics Gene Therapy CTX001 Gets PRIME Status
by Zacks Equity Research
CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals' CRISPR/Cas9 gene-editing therapy candidate, CTX001, gets Priority Medicines designation for treating sickle cell disease.
CRISPR Stocks: Buy or Trade?
by Kevin Cook
Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?
Vertex Seeks Nod for Cystic Fibrosis Drugs for Rare Mutations
by Zacks Equity Research
Vertex's (VRTX) sNDAs seek approval of Trikafta, Symdeko, and Kalydeco for additional rare mutations in the CFTR genes.
CRISPR Therapeutics AG (CRSP) Up 2.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRISPR Therapeutics (CRSP) Surges: Stock Moves 6% Higher
by Zacks Equity Research
CRISPR Therapeutics (CRSP) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Vertex (VRTX) Q2 Earnings & Sales Beat, Revenue Guidance Up
by Zacks Equity Research
Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -41.30% and -99.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will CRISPR Therapeutics AG (CRSP) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for CRISPR (CRSP) This Earnings Season?
by Zacks Equity Research
CRISPR Therapeutics (CRSP) is developing its lead gene-editing candidate for thalassemia and sickle cell disease. The company is expected to provide an update on its progress on the earnings call.
CRISPR Therapeutics (CRSP) Surges: Stock Moves 6.8% Higher
by Zacks Equity Research
CRISPR Therapeutics (CRSP) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity
by Benjamin Rains
Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...
Why Is CRISPR Therapeutics AG (CRSP) Up 22.9% Since Last Earnings Report?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bull of the Day: Vertex Pharma (VRTX)
by Kevin Cook
While COVID-19 interrupts clinical trials, the champ of cystic fibrosis is about to repeat another year of 37% revenue growth
Chart Radar: Buy Software, Sell Banks
by Kevin Cook
If a bigger pullback is unfolding in this over-valued market, now is the time to plan your big dip buys.
Vertex (VRTX) Q1 Earnings Beat, Trikafta Drives CF Revenues
by Zacks Equity Research
Vertex (VRTX) rides high on earnings and revenue beat in Q1.The company raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.50% and -97.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes CRISPR Therapeutics AG (CRSP) a New Buy Stock
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $39.54, moving +1.49% from the previous trading session.